Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Gossamer Bio Inc. (GOSS) Misses Q1 EPS by 7c
May 12, 2020 4:26 PM EDTGossamer Bio Inc. (NASDAQ: GOSS) reported Q1 EPS of ($0.87), $0.07 worse than the analyst estimate of ($0.80).
We are very pleased today to share initial results of the Gossamer teams great execution and hard work, including that we have successfully completed the interim analysis of the LEDA study of GB001, said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. We have begun initial Phase 3 planning and supportive activities, while awaiting final... More
